Regenxbio Inc (RGNX : NASDAQ)
Common Stock
$7.98
USD
+0.00 (%)
Last updated: 2026-09-17
Get RGNX alerts:
RGNX
Regenxbio Inc
WealthAwesomePerformance
1 Day
+0.44%
1 Week
-8.59%
1 Month
-29.57%
YTD
+1.01%
Key Statistics
Market Cap
$526.79M
52W High
$16.19
52W Low
$5.46
P/E Ratio
-
50 Day MA
$10.33
200 Day MA
$10.20
Beta
0.93
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $8.34 | $8.56 | $8.02 | $8.21 | $8.21 | 1,692,248 |
| 9/16/2026 | $7.93 | $7.99 | $7.64 | $7.98 | $7.98 | 1,229,336 |
| 9/15/2026 | $8.69 | $8.75 | $7.78 | $7.95 | $7.95 | 1,427,119 |
| 9/14/2026 | $8.58 | $8.73 | $8.49 | $8.69 | $8.69 | 858,446 |
| 9/11/2026 | $8.69 | $8.82 | $8.39 | $8.53 | $8.53 | 1,029,133 |
| 9/10/2026 | $8.63 | $8.79 | $8.47 | $8.56 | $8.56 | 1,172,100 |
| 9/9/2026 | $8.70 | $9.03 | $8.62 | $8.73 | $8.73 | 1,407,400 |
| 9/8/2026 | $8.95 | $8.95 | $8.60 | $8.76 | $8.76 | 998,700 |
| 9/4/2026 | $9.09 | $9.21 | $8.86 | $8.94 | $8.94 | 1,069,100 |
| 9/3/2026 | $9.56 | $9.56 | $9.00 | $9.20 | $9.20 | 839,200 |
Analyst Price Targets
Based on 12 analysts covering RGNX · as of Sep 17, 2026
Wall Street analysts forecast RGNX stock price to rise 197.3% over the next 12 months.
Consensus
Buy4.42 / 5.00
Avg. Target
US$23.73
+197.3% Upside
Current Price
US$7.98
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on RGNX's historical volatility
30-Day Vol
108.6%
Annualized
90-Day Vol
103.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$6.87
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$7.74 | US$5.32 – US$11.26 |
| 60 trading days | US$7.29 | US$4.29 – US$12.39 |
| 90 trading days | US$6.87 | US$3.59 – US$13.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Financials
- Revenue (TTM)
- $174.48M
- EBITDA
- $-148.78M
- Profit Margin
- -112.58%
- ROE (TTM)
- -137.63%
- EPS (Diluted)
- -3.78
- Book Value
- 1.32
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About RGNX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |